Suppr超能文献

局部促凝血作用增强:一种有助于重组凝血因子VIIa在血小板疾病中产生良好止血效果的机制。

Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.

作者信息

Galán Ana-María, Tonda Raúl, Pino Marcos, Reverter Juan Carlos, Ordinas Antonio, Escolar Ginés

机构信息

Hematherapy and Hemostasis Service, Hospital Clinic, Faculty of Medicine, IDIBAPS, Barcelona, Spain.

出版信息

Transfusion. 2003 Jul;43(7):885-92. doi: 10.1046/j.1537-2995.2003.00427.x.

Abstract

BACKGROUND

Recombinant FVIIa (rFVIIa) has been shown to improve hemostasis in patients with thrombocytopenia and to prevent or control bleeding episodes in patients with inherited deficiencies of major PLT glycoproteins, but the mechanism of action is not well understood.

STUDY DESIGN AND METHODS

Effects of rFVIIa on hemostasis were explored with an in vitro perfusion technique. Blood samples, from healthy donors or from patients with congenital defects of PLT glycoprotein IIb-IIIa (GPIIb-IIIa), were anticoagulated with low-molecular-weight heparin. Experimental thrombocytopenia (<6000 PLTs/microL) was induced by a filtration procedure. rFVIIa was added to blood samples at therapeutic concentrations. A severe GPIIb-IIIa impairment was also induced by exposure of normal blood samples to a specific antibody. Perfusion studies were performed through annular chambers containing damaged vascular segments. The presence of fibrin and PLTs on the perfused subendothelium was morphometrically quantified.

RESULTS

Under conditions of experimental thrombocytopenia, addition of rFVIIa enhanced fibrin formation in a dose-dependent manner (p < 0.05). Improvements in local fibrin generation and partial restoration of PLT interactions were also observed after incubation of blood from patients with Glanzmann's thrombasthenia with rFVIIa at 5 microg per mL (180 microg/kg). Similar improvements were observed in blood samples incubated with antibodies to GPIIb-IIIa. rFVIIa in whole normal blood also enhanced fibrin formation but PLT deposition was unaffected. Evaluation of prothrombin fragments 1 and 2 in the perfusates confirmed that rFVIIa increased thrombin generation in all cases.

CONCLUSION

Our data indicate that rFVIIa promotes a procoagulant activity at sites of vascular damage. This mechanism could explain the beneficial hemostatic effect of rFVIIa in patients with thrombocytopenia or with Glanzmann's thrombasthenia.

摘要

背景

重组凝血因子VIIa(rFVIIa)已被证明可改善血小板减少症患者的止血功能,并预防或控制主要血小板糖蛋白遗传性缺陷患者的出血发作,但其作用机制尚不完全清楚。

研究设计与方法

采用体外灌注技术探讨rFVIIa对止血的影响。来自健康供体或血小板糖蛋白IIb-IIIa(GPIIb-IIIa)先天性缺陷患者的血样用低分子量肝素抗凝。通过过滤程序诱导实验性血小板减少症(<6000个血小板/微升)。将治疗浓度的rFVIIa添加到血样中。通过将正常血样暴露于特异性抗体也可诱导严重的GPIIb-IIIa损伤。通过含有受损血管段的环形腔室进行灌注研究。对灌注的内皮下纤维蛋白和血小板的存在进行形态计量学定量。

结果

在实验性血小板减少症的条件下,添加rFVIIa以剂量依赖性方式增强纤维蛋白形成(p<0.05)。在将Glanzmann血小板无力症患者的血液与5微克/毫升(180微克/千克)的rFVIIa孵育后,还观察到局部纤维蛋白生成的改善和血小板相互作用的部分恢复。在用GPIIb-IIIa抗体孵育的血样中也观察到类似的改善。全正常血液中的rFVIIa也增强了纤维蛋白形成,但血小板沉积未受影响。对灌注液中凝血酶原片段1和2的评估证实,rFVIIa在所有情况下均增加了凝血酶生成。

结论

我们的数据表明,rFVIIa在血管损伤部位促进促凝血活性。这一机制可以解释rFVIIa对血小板减少症或Glanzmann血小板无力症患者有益的止血作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验